Through transcriptome analysis, we identified that a downstream target of the cGAS‐STING pathway, CXCL11, was upregulated in HRD tumors and could be used as a predictor of survival outcome. Here, CXCL11 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.